Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of REGN3500 in Healthy Adults
NCT02958436Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of itepekimab in asthma and chronic obstructive pulmonary disease (COPD) (5 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Aug 2016; status: completed.
02
Drugs
itepekimab
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02958436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958436.